Biodesix
Total Raised
$259.21MInvestors Count
11Deal Terms
7Funding, Valuation & Revenue
26 Fundings
Biodesix has raised $259.21M over 26 rounds.
Biodesix's latest funding round was a IPO for $75M on October 28, 2020.
Biodesix's latest post-money valuation is from October 2020.
Sign up for a free demo to see Biodesix's valuations in October 2020 and more.
Biodesix's 2020 revenue was $45.56M. Biodesix's most recent revenue is from 2020.
Sign up for a free demo to see revenue data from 2020 and more.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
10/28/2020 | IPO | $75M | 3 | |||
4/11/2020 | Loan - II | $3.5M | $45.56M FY 2020 | |||
12/20/2019 | Convertible Note - V | $16M | Undisclosed Investors | 2 | ||
8/22/2019 | Convertible Note - IV | |||||
10/23/2018 | Series G - II |
Date | 10/28/2020 | 4/11/2020 | 12/20/2019 | 8/22/2019 | 10/23/2018 |
|---|---|---|---|---|---|
Round | IPO | Loan - II | Convertible Note - V | Convertible Note - IV | Series G - II |
Amount | $75M | $3.5M | $16M | ||
Investors | Undisclosed Investors | ||||
Valuation | |||||
Revenue | $45.56M FY 2020 | ||||
Sources | 3 | 2 |
Biodesix Deal Terms
7 Deal Terms
Biodesix's deal structure is available for 7 funding rounds, including their IPO from October 28, 2020.
Round | IPO | Series E - IV | Series D | Series C | Series B |
|---|---|---|---|---|---|
Funding Date | |||||
Pre-Money Valuation | |||||
Post-Money Valuation | |||||
Amount Raised | |||||
Shares Authorized | |||||
Issuance Price | |||||
Dividend Rate | |||||
Liquidation Preferences | |||||
Liquidation Price | |||||
Participation | |||||
Conversion Price | |||||
Anti Dilution | |||||
General Voting | |||||
Board Voting | |||||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IPO | |||||||||||||||
Series E - IV | |||||||||||||||
Series D | |||||||||||||||
Series C | |||||||||||||||
Series B |
Biodesix Investors
11 Investors
Biodesix has 11 investors. Paycheck Protection Program invested in Biodesix's Loan - II funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
4/11/2020 | 4/11/2020 | 1 Loan - II | Government | DC | ||
8/30/2012 | 10/23/2018 | 10 Series D - II, Series E (2013), Series E - II (2014), Series E - III (2015), Series E - IV (2015), Series F (2016), Series F - II (2016), Convertible Note - III (2018), Series G (2018), Series G - II (2018) | Venture Capital | Illinois | ||
5/8/2018 | 10/23/2018 | 3 Convertible Note - III, Series G (2018), Series G - II (2018) | Venture Capital | Pennsylvania | ||
Asset/Investment Management | Vermont | |||||
Debt & Specialty Finance | New York |
First funding | 4/11/2020 | 8/30/2012 | 5/8/2018 | ||
|---|---|---|---|---|---|
Last Funding | 4/11/2020 | 10/23/2018 | 10/23/2018 | ||
Investor | |||||
Rounds | 1 Loan - II | 10 Series D - II, Series E (2013), Series E - II (2014), Series E - III (2015), Series E - IV (2015), Series F (2016), Series F - II (2016), Convertible Note - III (2018), Series G (2018), Series G - II (2018) | 3 Convertible Note - III, Series G (2018), Series G - II (2018) | ||
Board Seats | |||||
Type | Government | Venture Capital | Venture Capital | Asset/Investment Management | Debt & Specialty Finance |
Location | DC | Illinois | Pennsylvania | Vermont | New York |
Biodesix Acquisitions
2 Acquisitions
Biodesix acquired 2 companies. Their latest acquisition was OncImmune - Lab and IPN Testing on June 28, 2019.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
6/28/2019 | Acquired Unit | 2 | ||||
7/9/2018 | Series C |
Date | 6/28/2019 | 7/9/2018 |
|---|---|---|
Investment Stage | Series C | |
Companies | ||
Valuation | ||
Total Funding | ||
Note | Acquired Unit | |
Sources | 2 |
Compare Biodesix to Competitors
ProteoGenix is an antibody production company specializing in the biopharmaceutical sector. The company offers services including custom antibody development, monoclonal and polyclonal antibody production, antibody engineering, and protein expression services. ProteoGenix serves pharmaceutical and biotech companies with their therapeutic antibody discovery and assay development needs. It was founded in 2002 and is based in Costa Mesa, California.
Hx Diagnostics offers rapid diagnostics for seasonal and emerging infectious diseases.
AngioLogix is a provider of cardiovascular health diagnostics.
Sober Steering is a company that develops vehicle safety technology in the automotive industry. Their main offering is a biosensor system embedded in the steering wheel that detects intoxication through natural hand interactions, utilizing non-invasive sensing technology to identify ethanol in the bloodstream. If intoxication is detected, the system engages a transmission interlock to immobilize the vehicle. It was founded in 2009 and is based in Boca Raton, Florida.
XDx is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression testing in the areas of transplant medicine and autoimmunity. Per the company, they have developed a proprietary method of utilizing gene expression in blood that aims to provide a new tool for physicians to manage the care of heart transplant patients. The molecular expression technology developed and implemented by XDx in heart transplant patient management is currently being explored to assist with other diseases that involve the immune system.
Cybergene focuses on the MedTech sector, specializing in vitro diagnostics. It offers a range of diagnostic products including prenatal diagnostics for chromosomal conditions, pregnancy loss analysis, and male infertility testing. Its main products are the ChromoQuant CE-IVD kits. It was founded in 1995 and is based in Solna, Sweden.
Loading...